Welcome to GenVisc® 850

GENVISC 850

AN ALTERNATIVE “SECOND GENERATION”, NON-AVIAN DERIVED SODIUM HYALURONATE FOR YOU AND YOUR PATIENTS

  • GenVisc 850 is comparable to Supartz/Supartz FX in purity, chemical composition, and rheological & molecular weight characteristics 1
  • GenVisc 850 has clinical efficacy & safety demonstrated to be non-inferior from Supartz / Supartz FX 2, 3
  • GenVisc 850 has same established treatment schedule as Supartz/Supartz FX including safety of repeat treatment 4

Click here for Full Prescribing and Patient Information.

PHYSICIAN'S LEAVE BEHIND

To learn more about GenVisc 850, please download our full brochure that describes, added value, order information, coverage and more.

GenVisc 850 Support Hotline

1-844-GENVISC (1-844-436-8472)
Fax: (866) 227-9248

Read important
Safety Information

References:

1. FDA summary of safety and effectiveness data (SSED). GenVisc 850. http://www.accessdata.fda.gov/cdrh_docs/pdf14/p140005b.pdf. Accessed December 22, 2015.

2. GenVisc 850 (sodium hyaluronate) [prescribing information]. Doylestown, PA: OrthogenRx, Inc; 2015.

3. Xin Y, Jianhao L, Tianshen S, et al. The efficacy and safety of sodium hyaluronate injection (Adant®) in treating degenerative osteoarthritis, a multi-center, randomized, double-blind, positive-drug parallel-controlled and non-inferiority clinical study. Int J Rheum Dis. 2015.

4. Supartz PI, GenVisc PI.

Supartz® is a registered trademark of Seikagaku Corp.